MondegarAI
Birchview Capital, LP

Q1 2024 · 13F-HR/A

Birchview Capital, LPholdings as filed

Filed 2025-06-30 · accession 0001618205-25-000005

$122.7M
Reported value
59
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
110122108BMYBRISTOL-MYERS SQUIBB CO$38.2M31.1%703,606CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$10.7M8.68%77,240CommonSOLE
09075X108BIODESIX INC COM RST$7.6M6.22%5,348,273CommonSOLE
05479K106ELUTELUTIA INC$5.2M4.25%1,655,184CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$4.6M3.77%250,400CommonSOLE
69047Q102OVVOVINTIV INC$4.4M3.56%84,200CommonSOLE
G72800108PRTAPROTHENA CORP PLC$4.2M3.42%169,574CommonSOLE
74838J101QUIDELORTHO CORP$3.1M2.55%65,203CommonSOLE
82710M100SILKUSDSILK ROAD MEDICAL INC$2.9M2.36%158,094CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$2.8M2.31%210,000CommonSOLE
71944F106PHRPHREESIA INC$2.7M2.24%114,700CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP$2.5M2.06%11,000CommonSOLE
574795100MASIMASIMO CORP$2.2M1.83%15,280CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$2.2M1.76%320,930CommonSOLE
415858109HROWHARROW HEALTH INC$2.0M1.62%150,000CommonSOLE
256086109DCGODOCGO INC$1.9M1.51%460,000CommonSOLE
45720L107INBXUSDINHIBRX INC$1.7M1.38%48,448CommonSOLE
294600101ETRNUSDEQUITRANS MIDSTREAM CORPORATIO$1.7M1.35%133,050CommonSOLE
05463X106AXGNAXOGEN INC$1.4M1.14%173,000CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$1.4M1.13%48,000CommonSOLE
G01767105ALKSALKERMES PLC$1.4M1.10%50,000CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$1.3M1.03%50,000CommonSOLE
02081G201ATECALPHATEC HOLDINGS INC$1.2M0.99%88,000CommonSOLE
88025U109TXG10X GENOMICS INC$1.1M0.92%30,000CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$1.1M0.86%18,000CommonSOLE
723787107PXDEURPIONEER NATURAL RESOURCES CO$997,5000.81%3,800CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$940,6200.77%122,000CommonSOLE
74340E103PGNYPROGYNY INC$839,3000.68%22,000CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$709,4460.58%469,832CommonSOLE
23282W605CYTKCYTOKINETICS INC$701,1000.57%10,000CommonSOLE
19249H103CHRSCOHERUS BIOSCIENCES INC$645,3000.53%270,000CommonSOLE
04335A105ARVNARVINAS INC$619,2000.50%15,000CommonSOLE
G5269C101KINIKSA PHARMACEUTICALS LTD$591,9000.48%30,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$545,5600.44%46,000CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$492,2000.40%10,000CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$463,4000.38%7,000CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$430,5000.35%10,000CommonSOLE
230031106CGEMCULLINAN ONCOLOGY INC$427,9430.35%25,114CommonSOLE
09609G100BLUEBIRD BIO INC$411,1360.34%321,200CommonSOLE
40637H109HALOHALOZYME THERAPEUTICS INC$406,8000.33%10,000CommonSOLE
G11196105BIOHAVEN PHARMACEUTICAL HOLDING CO LTD$402,7920.33%7,365CommonSOLE
3621LQ109GTHXEURG1 THERAPEUTICS INC$345,6000.28%80,000CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$329,8400.27%28,000CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$323,6500.26%2,500CommonSOLE
00430H102ACCELERATE DIAGNOSTICS INC$321,9860.26%325,239CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$319,2000.26%4,000CommonSOLE
14843C105CSTLCASTLE BIOSCIENCES INC$310,1000.25%14,000CommonSOLE
98401F105XNCRXENCOR INC$272,1990.22%12,300CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$252,1600.21%16,000CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$246,8000.20%40,000CommonSOLE
12674W109CABACABALETTA BIO INC$170,6000.14%10,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$163,0480.13%138,176CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$158,4000.13%28,800CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$147,5000.12%10,000CommonSOLE
901384107TSVT*2SEVENTY BIO INC$106,1070.09%19,833CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$101,6000.08%20,000CommonSOLE
N44821101IFRXINFLARX NV$77,0000.06%50,000CommonSOLE
71902K105CERO THERAPEUTICS HOLDINGS INC$39,8240.03%12,972CommonSOLE
98585K102YIELD10 BIOSCIENCE INC$7,1250.01%18,750CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.